Ikarian Capital’s Atara Biotherapeutics ATRA Stock Holding History

Ikarian Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-17,072	Closed	-$5.53M	–	235
2020 Q3	$5.53M	Buy	+17,072	New	+$5.81M	0.4%	64

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ikarian Capital's ATRA Position: Q4 2020 in Review

Ikarian Capital sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 17,072 shares — an estimated $5.53M sold.

Ikarian Capital first reported a position in ATRA in Q3 2020 and held it in 1 quarter. The position peaked at $5.53M in Q3 2020. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

Ikarian Capital reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
Ikarian Capital sold 17,072 Atara Biotherapeutics shares in Q4 2020, an estimated $5.53M.
Ikarian Capital first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 1 quarter.
Ikarian Capital's Atara Biotherapeutics position peaked at $5.53M in Q3 2020.
148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.